欧州医薬品庁(EMA)が、neratinibについて、HER2陽性早期乳がんの術後療法薬としての適応承認を支持

EMA Recommends Granting a Marketing Authorisation for Neratinib After Re-examining Its Negative Opinion for This Medicine


On 28 June 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP), following a re-examination procedure, adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product neratinib (Nerlynx), intended for the adjuvant treatment of adult patients with breast cancer.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*